Our top pick for
Organogenesis Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 835 staff and has a trailing 12-month revenue of around USD$306.1 million.
|52-week range||USD$2.4722 - USD$17.11|
|50-day moving average||USD$12.1072|
|200-day moving average||USD$6.5649|
|Wall St. target price||USD$14.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.581|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$11.5 million.
The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$306.1 million|
|Operating margin TTM||1.27%|
|Gross profit TTM||USD$185 million|
|Return on assets TTM||1.16%|
|Return on equity TTM||-12.63%|
|Market capitalisation||USD$2.1 billion|
TTM: trailing 12 months
There are currently 1.0 million Organogenesis shares held short by investors – that's known as Organogenesis's "short interest". This figure is 0.7% up from 1.0 million last month.
There are a few different ways that this level of interest in shorting Organogenesis shares can be evaluated.
Organogenesis's "short interest ratio" (SIR) is the quantity of Organogenesis shares currently shorted divided by the average quantity of Organogenesis shares traded daily (recently around 1.0 million). Organogenesis's SIR currently stands at 0.99. In other words for every 100,000 Organogenesis shares traded daily on the market, roughly 990 shares are currently held short.
However Organogenesis's short interest can also be evaluated against the total number of Organogenesis shares, or, against the total number of tradable Organogenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Organogenesis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Organogenesis shares in existence, roughly 10 shares are currently held short) or 0.0154% of the tradable shares (for every 100,000 tradable Organogenesis shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Organogenesis.
Find out more about how you can short Organogenesis stock.
We're not expecting Organogenesis to pay a dividend over the next 12 months.
Over the last 12 months, Organogenesis's shares have ranged in value from as little as $2.4722 up to $17.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.5354. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.